AIMS: To determine whether expression of Smad4, a tumour suppressor found to be absent in 10% of colorectal cancer (CRC), is associated with outcomes in patients with CRC. METHODS: Tumour samples from 241 consecutive patients with CRC who underwent upfront colon resection between 2005 and 2009 were obtained. Triplicate tissue cores from resected primary colon tumours and matched normal controls were used to construct the tissue microarrays (TMAs). We examined the expression of Smad4 using immunohistochemistry. Clinicopathological records were obtained for all patients. TMAs were reviewed by two pathologists and scored as either 'positive' or 'negative' for nuclear staining. In total, 21 of 241 tumours (8.6%) were Smad4 negative. RESULTS: Loss of Smad4 expression correlated with significantly worse overall survival (OS) (p=0.011) and disease-free survival (DFS) (p=0.024). Patients with loss of Smad4 expression had a median OS of 31 months compared with 89 months positive Smad4 expression. Loss of Smad4 remained significant on multivariate analysis for OS (p=0.0097). In patients with node-positive disease, loss of Smad4 predicts for worse DFS (p=0.012). In patients with metastatic and recurrent disease, Smad4 loss predicts for worse OS (p=0.012). Of the patients that received capecitabine over the course of their treatment, those with Smad4 loss (n=13) had significantly worse DFS (p=0.003) and OS (p=0.0007). CONCLUSIONS: Loss of Smad4 expression is associated with worse DFS and OS in multiple subsets of patients with CRC. Further studies are required to validate our findings and ascertain the role of Smad4 status in the management of this disease. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: To determine whether expression of Smad4, a tumour suppressor found to be absent in 10% of colorectal cancer (CRC), is associated with outcomes in patients with CRC. METHODS:Tumour samples from 241 consecutive patients with CRC who underwent upfront colon resection between 2005 and 2009 were obtained. Triplicate tissue cores from resected primary colon tumours and matched normal controls were used to construct the tissue microarrays (TMAs). We examined the expression of Smad4 using immunohistochemistry. Clinicopathological records were obtained for all patients. TMAs were reviewed by two pathologists and scored as either 'positive' or 'negative' for nuclear staining. In total, 21 of 241 tumours (8.6%) were Smad4 negative. RESULTS: Loss of Smad4 expression correlated with significantly worse overall survival (OS) (p=0.011) and disease-free survival (DFS) (p=0.024). Patients with loss of Smad4 expression had a median OS of 31 months compared with 89 months positive Smad4 expression. Loss of Smad4 remained significant on multivariate analysis for OS (p=0.0097). In patients with node-positive disease, loss of Smad4 predicts for worse DFS (p=0.012). In patients with metastatic and recurrent disease, Smad4 loss predicts for worse OS (p=0.012). Of the patients that received capecitabine over the course of their treatment, those with Smad4 loss (n=13) had significantly worse DFS (p=0.003) and OS (p=0.0007). CONCLUSIONS: Loss of Smad4 expression is associated with worse DFS and OS in multiple subsets of patients with CRC. Further studies are required to validate our findings and ascertain the role of Smad4 status in the management of this disease. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
CANCER; CANCER RESEARCH; COLORECTAL CANCER
Authors: Jinru Shia; Nikolaus Schultz; Deborah Kuk; Efsevia Vakiani; Sumit Middha; Neil H Segal; Jaclyn F Hechtman; Michael F Berger; Zsofia K Stadler; Martin R Weiser; Jedd D Wolchok; C Richard Boland; Mithat Gönen; David S Klimstra Journal: Mod Pathol Date: 2016-12-16 Impact factor: 7.842
Authors: Isaac Wasserman; Lik Hang Lee; J Joshua Smith; Shuji Ogino; Michael R Marco; Chao Wu; Xi Chen; Jashodeep Datta; Eran Sadot; Bryan Szeglin; Jose G Guillem; Philip B Paty; Martin R Weiser; Garrett M Nash; Leonard Saltz; Afsar Barlas; Katia Manova-Todorova; Srijaya Prakash Babu Uppada; Arthur E Elghouayel; Peter Ntiamoah; Jonathan N Glickman; Tsuyoshi Hamada; Keisuke Kosumi; Kentaro Inamura; Andrew T Chan; Reiko Nishihara; Andrea Cercek; Karuna Ganesh; Nancy E Kemeny; Punita Dhawan; Rona Yaeger; Charles L Sawyers; Julio Garcia-Aguilar; Marios Giannakis; Jinru Shia Journal: Clin Cancer Res Date: 2018-12-26 Impact factor: 12.531
Authors: Maurice Phm Jansen; John Wm Martens; Jean Ca Helmijr; Corine M Beaufort; Ronald van Marion; Niels Mg Krol; Kim Monkhorst; Anita Mac Trapman-Jansen; Marion E Meijer-van Gelder; Marjolein Ja Weerts; Diana E Ramirez-Ardila; Hendrikus Jan Dubbink; John A Foekens; Stefan Sleijfer; Els Mjj Berns Journal: Oncotarget Date: 2016-07-12
Authors: Anna V Kudryavtseva; Anastasia V Lipatova; Andrew R Zaretsky; Alexey A Moskalev; Maria S Fedorova; Anastasiya S Rasskazova; Galina A Shibukhova; Anastasiya V Snezhkina; Andrey D Kaprin; Boris Y Alekseev; Alexey A Dmitriev; George S Krasnov Journal: Oncotarget Date: 2016-08-16
Authors: Xu Jia; Chandrakumar Shanmugam; Ravi K Paluri; Nirag C Jhala; Michael P Behring; Venkat R Katkoori; Shajan P Sugandha; Sejong Bae; Temesgen Samuel; Upender Manne Journal: Oncotarget Date: 2017-03-21